| Literature DB >> 20513086 |
Nuria Tormo1, Carlos Solano, Isabel Benet, José Nieto, Rafael de la Cámara, Ana Garcia-Noblejas, María Angeles Clari, Marifina Chilet, Javier López, Juan Carlos Hernández-Boluda, María José Remigia, David Navarro.
Abstract
The dynamics of CMV pp65 and IE-1-specific IFNgamma-producing CD8(+) (IFNgamma CD8(+)) and CD4(+) (IFNgamma CD4(+)) T cells and CMV DNAemia were assessed in 19 pre-emptively treated episodes of active CMV infection. Peripheral counts of IFNgamma CD8(+) and IFNgamma CD4(+) T cells inversely correlated with CMV DNAemia levels (P = <0.001 and P = 0.003, respectively). A threshold value of 1.3 cells/microl predicting CMV DNAemia clearance was established for IFNgamma CD8(+) T cells (PPV, 100%; NPV, 93%) and for IFNgamma CD4(+) T cells (PPV, 100%; NPV, 75%). Undetectable T-cell responses were usually observed at the time of initiation of pre-emptive therapy. Either a rapid (within 7 days) or a delayed (median 31 days) expansion of both T-cell populations concomitant with CMV DNAemia clearance was observed in 5 and 8 episodes, respectively. An inconsistent or a lack of expansion of both T-cell subsets was related to a persistent CMV DNAemia. Robust and maintained CMV-specific T-cell responses after CMV DNAemia clearance and cessation of antiviral therapy were associated with a null incidence of relapsing infections at least during the following month. Data obtained in the present study may be helpful in the design of therapeutic strategies for the management of active CMV infections in the allo-SCT recipient. (c) 2010 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20513086 DOI: 10.1002/jmv.21799
Source DB: PubMed Journal: J Med Virol ISSN: 0146-6615 Impact factor: 2.327